A detailed history of Northern Trust Corp transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 17,798 shares of XLO stock, worth $16,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,798
Previous 17,798 -0.0%
Holding current value
$16,908
Previous $9,000 111.11%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$2.55 - $3.46 $2,297 - $3,117
901 Added 5.33%
17,798 $46,000
Q1 2023

May 15, 2023

BUY
$2.66 - $4.28 $10,632 - $17,107
3,997 Added 30.98%
16,897 $53,000
Q2 2022

Aug 12, 2022

SELL
$2.08 - $7.2 $105,399 - $364,845
-50,673 Reduced 79.71%
12,900 $38,000
Q1 2022

May 13, 2022

BUY
$6.63 - $16.05 $3,573 - $8,650
539 Added 0.86%
63,573 $449,000
Q4 2021

Feb 08, 2022

BUY
$9.69 - $25.11 $610,799 - $1.58 Million
63,034 New
63,034 $1.01 Million

Others Institutions Holding XLO

About Xilio Therapeutics, Inc.


  • Ticker XLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,471,600
  • Market Cap $26.1M
  • Description
  • Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...
More about XLO
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.